Galecto (GLTO)
Preclinical biotech targeting mutant calreticulin blood disorders.
$21.58
At close−0.75 (−3.36%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions64 holders · as of Mar 31, 2026 | 90.71% | 56.00M shares | |
| Insiders6 holders · as of Feb 12, 2026 | 0.97% | 599.5K shares | |
| Otherremainder | 8.32% | 5.14M shares |
61.74M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (61.74M in the company's Sep 3, 2026 report, 1.60M elsewhere); stakes use the report.
Institutions13F
No 13F holders on record.
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Fairmount Funds Management LLCincl. Tomas Kiselak, Peter Evan Harwin +2 more | 19.99% | 13D | Feb 11, 2026 ↗ | |
| FMR LLC | 15.00% | 238.9K | 13G | Dec 5, 2025 ↗ |
| Avoro Capital Advisors LLC | 6.27% | 13G | May 15, 2026 ↗ | |
| Venrock Healthcare Capital Partners III, L.P. | 6.00% | 13G | Feb 17, 2026 ↗ | |
| BlackRock, Inc. | 5.10% | 13G | Jul 28, 2026 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jan 2, 2026 | Lori Firmaniofficer: Chief Financial Officer | Sale | 135 | $21.41 | 931 |
| Jan 2, 2026 | Garrett Winslowofficer: General Counsel | Sale | 255 | $21.38 | 1,854 |
| Jan 2, 2026 | Hans T. Schambyedirector, officer: Chief Executive Officer | Sale | 700 | $21.38 | 4,682 |
CongressHouse and Senate disclosures
Not reported.